Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Vigonvita Life Sciences / Equity Capital Markets

<ul>
<li>Vigonvita is looking to raise at least US$100 million via a Hong Kong listing.</li>
<li>Vigonvita has commercialized COVID-19 anti-viral drug and is expanding the indication to RSV. </li>
<li>The main contributor to the company's develop is not holding a key management role.</li>
</ul>


Vigonvita is looking to raise at least US$100 million via a Hong Kong listing.
Vigonvita has commercialized COVID-19 anti-viral drug and is expanding the indication to RSV. 
The main contributor to the company's develop is not holding a key management role.


Vigonvita Life Sciences (旺山旺水) Pre-IPO Tearsheet

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vigonvita Life Sciences (VVL HK)

Vigonvita Life Sciences (旺山旺水) Pre-IPO Tearsheet

Vigonvita seeks US$100M in Hong Kong IPO for COVID-19 drug expansion. It has commercialized COVID-19 drugs in the past and is looking to expand...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Vigonvita Life Sciences (旺山旺水) Pre-IPO Tearsheet

​Vigonvita seeks US$100M in Hong Kong IPO for COVID-19 drug expansion. It has commercialized COVID-19 drugs in the past and is looking to expand...

Ke Yan, CFA, FRM

Vigonvita seeks US$100M in Hong Kong IPO for COVID-19 drug expansion. It has commercialized COVID-19 drugs in the past and is looking to expand...